Sipai Health Technology Co., Ltd. (HK:0314)
:0314
Top Page
Sipai Health Technology Co., Ltd.
(0314)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.50
▲(0.81% Upside)
Action:ReiteratedDate:01/16/26
The score is held down primarily by weak financial fundamentals—ongoing losses and negative operating/free cash flow. Technicals provide some offset with moderate bullish/neutral momentum, but valuation remains unattractive/unclear due to the negative P/E and lack of dividend data.
Positive Factors
Business model & product focus
Sipai's core focus on diagnostic tools and health monitoring for clinical and personal use establishes a durable product-led business model. Serving both clinical and consumer markets supports multiple adoption paths, helping sustained revenue potential as healthcare digitizes and chronic care management grows.
Negative Factors
Persistent unprofitability
Sustained negative profitability erodes retained earnings and limits ability to self-fund growth or absorb shocks. Prolonged negative margins indicate structural cost or pricing issues that, unless resolved, will continue to impair ROE and constrain long-term reinvestment into products and market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model & product focus
Sipai's core focus on diagnostic tools and health monitoring for clinical and personal use establishes a durable product-led business model. Serving both clinical and consumer markets supports multiple adoption paths, helping sustained revenue potential as healthcare digitizes and chronic care management grows.
Read all positive factors
Sipai Health Technology Co., Ltd. (0314) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.60B
Dividend YieldN/A
Average Volume (3M)2.05M
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-26.21%
EPS Growth-29.70%
CountryHK
Employees3,236
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Plans
Share Statistics
EPS (TTM)-0.07
Shares Outstanding765,578,100
10 Day Avg. Volume1,436,880
30 Day Avg. Volume2,048,921
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.67
Price to Sales (P/S)0.72
P/FCF Ratio-48.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$1.92B
Sipai Health Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, a...
How the Company Makes Money
Sipai Health Technology Co., Ltd. generates revenue primarily through the sale of its medical devices and health management solutions. The company has established key revenue streams from direct product sales to hospitals, healthcare providers, an...
Sipai Health Technology Co., Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.43B | 4.57B | 4.71B | 4.12B | 3.47B | 2.70B |
| Gross Profit | 332.69M | 386.43M | 412.45M | 334.83M | 281.06M | 186.86M |
| EBITDA | -227.95M | -259.52M | -226.10M | -1.35B | -726.84M | -1.02B |
| Net Income | -317.52M | -323.74M | -255.77M | -1.37B | -3.74B | -1.04B |
Balance Sheet | ||||||
| Total Assets | 1.83B | 2.27B | 2.82B | 2.93B | 2.89B | 2.48B |
| Cash, Cash Equivalents and Short-Term Investments | 597.85M | 919.77M | 1.13B | 1.53B | 1.61B | 1.67B |
| Total Debt | 24.70M | 66.49M | 67.56M | 67.76M | 7.52B | 63.59M |
| Total Liabilities | 876.01M | 1.06B | 1.18B | 1.10B | 8.32B | 4.27B |
| Stockholders Equity | 995.88M | 1.23B | 1.62B | 1.84B | -5.43B | -1.80B |
Cash Flow | ||||||
| Free Cash Flow | -60.00M | -67.91M | -139.24M | -193.87M | -643.33M | -204.11M |
| Operating Cash Flow | -58.16M | -59.45M | -133.50M | -182.07M | -621.92M | -192.12M |
| Investing Cash Flow | 93.73M | -622.00K | -720.81M | 1.03B | -1.02B | 319.62M |
| Financing Cash Flow | -63.31M | -184.06M | -120.55M | 81.69M | 559.29M | 1.31B |
Sipai Health Technology Co., Ltd. Technical Analysis
Negative
2.48
Price Trends
2.45
Negative
2.44
Negative
3.51
Negative
Market Momentum
-0.09
Positive
36.60
Neutral
6.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0314, the sentiment is Negative. The current price of 2.48 is above the 20-day moving average (MA) of 2.44, above the 50-day MA of 2.45, and below the 200-day MA of 3.51, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.60 is Neutral, neither overbought nor oversold. The STOCH value of 6.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0314.
Sipai Health Technology Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$6.46B | 18.20 | 6.19% | 2.76% | 13.59% | 6.31% | |
73 Outperform | HK$7.54B | 20.75 | 11.20% | ― | 14.06% | 3.02% | |
66 Neutral | HK$1.85B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.24B | -18.13 | -11.27% | ― | 29.25% | 9.02% | |
44 Neutral | HK$1.60B | -18.02 | -18.16% | ― | -26.21% | -29.70% | |
44 Neutral | HK$2.16B | -3.21 | -137.11% | ― | ― | -18.99% |
* Healthcare Sector Average
HK:0314
Sipai Health Technology Co., Ltd.
2.11
-2.72
-56.31%
HK:9996
Peijia Medical Ltd.
6.32
1.95
44.62%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
35.70
8.85
32.96%
HK:1763
China Isotope & Radiation Corp.
20.20
9.43
87.56%
HK:1931
IVD Medical Holding Limited
1.14
-0.56
-32.94%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.50
-2.46
-35.34%
Sipai Health Technology Co., Ltd. Corporate Events
Sipai Health Technology Adds Independent Director to Nomination Committee
Dec 22, 2025
Sipai Health Technology Co., Ltd., a Cayman Islands–incorporated company listed in Hong Kong, operates with a board structure that includes executive, non-executive and independent non-executive directors, reflecting typical governance pract...
Sipai Health Technology Outlines Board and Committee Composition
Dec 22, 2025
Sipai Health Technology has announced the current composition of its board of directors and the allocation of roles across four key board committees. The board is led by executive chairman Ma Xuguang alongside executive director Li Ji, non-executi...
Sipai Health Formalizes Nomination Committee Governance Framework
Dec 22, 2025
Sipai Health Technology Co., Ltd., a Cayman Islands-incorporated company listed in Hong Kong, operates under a board structure that includes various specialized committees to oversee governance and compliance with applicable listing and regulatory...
Sipai Health Technology Updates on Share Schemes
Oct 16, 2025
Sipai Health Technology Co., Ltd., a company incorporated in the Cayman Islands, has issued a supplemental announcement to its annual report for the year ended December 31, 2024. The announcement provides additional details on the company’s ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.